Infectious Diseases Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Department of Internal Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
Turk J Med Sci. 2020 Apr 9;50(2):354-359. doi: 10.3906/sag-1907-82.
BACKGROUND/AIM: Nonalcoholic fatty liver disease (NAFLD) is known to be the most prevalent chronic liver disease all over the world. The incidence of this disease has dramatically increased during the last decade. Studies have shown a strong relationship between the level of ferritin and the severity of NAFLD. The objective of the present study was to assess the effect of adding Hijamat, as an iron reducing procedure, to standard lifestyle modification on the improvement of insulin resistance and liver enzymes in patients with NAFLD.
One hundred and twenty NAFLD patients participated in a randomized, controlled, single-blind trial design of study. The control group received counselling for nutrition and physical activity for a period of 6 months. The treatment group received the above items plus Hijamat for 3 times during 1 month. Ultrasound images of liver, HOMA-IR, and laboratory data including ALT, AST were assessed pre- and postintervention.
At the end of the study, a significant decrease was demonstrated in the serum level of HOMA-IR (–1.30 ± 0.88 vs –.02 ± 0.47, P < 0.001) and serum levels of ALT (–6.50 ± 4.92 vs –2.38 ± 3.92, P < 0.001) and AST (–2.78 ± 4.29 vs –1.30 ± 2.33, P = 0.021) in the Hijamat group were compared to the control group. Ultrasound images of the liver improved in 23.3% of the patients in the Hijamat group, while the rate of improvement in the control group was 10% (P = 0.050). Hijamat therapy was safe and tolerable in this trial.
Hijamat resulted in a relative improvement in fatty liver severity and improved HOMA-IR and liver enzymes more than lifestyle modification alone in patients with NAFLD.
背景/目的：非酒精性脂肪性肝病（NAFLD）是全世界最常见的慢性肝病。在过去十年中，这种疾病的发病率显著增加。研究表明，铁蛋白水平与 NAFLD 的严重程度之间存在很强的关系。本研究的目的是评估在标准生活方式改变的基础上增加 Hijamat（一种降低铁含量的程序）对改善 NAFLD 患者胰岛素抵抗和肝酶的效果。
120 名 NAFLD 患者参与了一项随机、对照、单盲试验设计研究。对照组接受营养和身体活动咨询，为期 6 个月。治疗组在 1 个月内接受上述项目加 Hijamat 3 次。在干预前后评估肝脏超声图像、HOMA-IR 和包括 ALT、AST 在内的实验室数据。
研究结束时，Hijamat 组的血清 HOMA-IR 水平显著下降（–1.30 ± 0.88 对 –0.02 ± 0.47，P < 0.001），血清 ALT（–6.50 ± 4.92 对 –2.38 ± 3.92，P < 0.001）和 AST（–2.78 ± 4.29 对 –1.30 ± 2.33，P = 0.021）水平也显著下降，与对照组相比。Hijamat 组中有 23.3%的患者肝脏超声图像改善，而对照组的改善率为 10%（P = 0.050）。在这项试验中，Hijamat 疗法是安全且可耐受的。
Hijamat 可相对改善脂肪肝严重程度，并改善 HOMA-IR 和肝酶，优于单纯生活方式改变，可用于 NAFLD 患者。
